Sanofi has retreated from a plan to file its anti-OX40L antibody amlitelimab for approval as a treatment for atopic dermatitis (AD) and will abandon development of the drug in this indication. The decision, announced this morning, comes despite Sanofi's assertions earlier this year that it planned to file amlitelimab in AD on the strength of the phase 3 SHORE and COAST studies. In a statement, Sanofi said that the decision not to submit amlitelimab for approval "was made as part of an ongoing strategic assessment of the pipeline." The decision leaves Sanofi more reliant on two other pipeline projects – anti-CD40L antibody frexalimab and orally-active TNF blocker SAR441566 – as it prepares for the potential loss of patent protection for Dupixent in the early 2030s. "Sanofi will work closely with investigators, site teams, and regulatory authorities to ensure a wind-down of ongoing amlitelimab AD studies, with appropriate transition of care for all enrolled patients."